General Biosystems, Inc, 1910 Sedwick Road STE 100D, Durham, NH (2025)

General Biosystems, Inc. is a US-based biotech company. It has a passion to understand how genetic information is stored and programmed in DNA and how it is used to direct various biological processes. With this knowledge, it develops innovative technologies and instruments to program and physically write or print new genetic codes. The new codes will form the blueprints for novel or improved biological functions and biological systems. These new biosystems will have broad applications and benefit human life and society in major ways.

02/14/2022

Heart-disease risk soars after COVID

Massive study shows a long-term, substantial rise in risk of cardiovascular disease, including heart attack and stroke, after a SARS-CoV-2 infection.

Even a mild case of COVID-19 can increase a person’s risk of cardiovascular problems for at least a year after diagnosis, a new study1 shows. Researchers found that rates of many conditions, such as heart failure and stroke, were substantially higher in people who had recovered from COVID-19 than in similar people who hadn’t had the disease.

What’s more, the risk was elevated even for those who were under 65 years of age and lacked risk factors, such as obesity or diabetes.

People who had recovered from COVID-19 showed stark increases in 20 cardiovascular problems over the year after infection. For example, they were 52% more likely to have had a stroke than the contemporary control group, meaning that, out of every 1,000 people studied, there were around 4 more people in the COVID-19 group than in the control group who experienced stroke.

The risk of heart failure increased by 72%, or around 12 more people in the COVID-19 group per 1,000 studied. Hospitalization increased the likelihood of future cardiovascular complications, but even people who avoided hospitalization were at higher risk for many conditions.

01/26/2022

Immune cells still recognize Omicron variant

Omicron’s genome is loaded with mutations — more than 30 in the region that codes for the spike protein, used in COVID-19 vaccines — meaning that the efficacy of antibodies raised against previous variants could be compromised.

When it comes to coronavirus immunity, antibodies have stolen the limelight. Researchers are monitoring people’s levels of antibodies — particularly ‘neutralizing antibodies’ that directly prevent the virus from replicating — with bated breath. A drop in neutralizing-antibody levels correlates with an increased risk of symptomatic infection. Antibodies are also easier to study than T cells, making it easier to analyse them in large, international vaccine trials.

But the rise of coronavirus variants has shown how fragile antibody-based immunity can be in the face of a changing virus. Neutralizing antibodies bind to a handful of regions on the SARS-CoV-2 spike protein, used as a template for many COVID-19 vaccines. Mutate those sites, and antibody protection fades.

T cells, however, are more resilient. These cells perform a variety of immune functions, including acting as ‘killer’ cells that destroy virus-infected cells. By killing infected cells, T cells can limit the spread of infection — and potentially reduce the chance of serious illness.

Omicron overpowers key COVID antibody treatments in early tests

T-cell levels do not tend to fade as quickly as antibodies after an infection or vaccination. And because T cells can recognize many more sites along the spike protein than can antibodies, they are better able to recognize mutated variants. “What sounds like a lot of mutations doesn’t dent the T-cell response,” says Burgers.

So far, computer and lab analyses suggest that this is the case for Omicron. Several research groups have cross-referenced the mutations in Omicron with sites in the SARS-CoV-2 genome that are known targets of T cells. They have found that the majority of sites that T cells recognize are present in Omicron.

Gene Synthesis Oligo Synthesis Site-directed Mutagenesis DNA Cloning Omicron

01/24/2022

Promotions for new customer

First order, 15% discount

Each discount can only be used once per order.

General Biosystems, Inc. reserves the final right of this promotion.

01/21/2022

To meet your needs to the fullest extent

Address

1910 Sedwick Road STE 100D
Durham, NH
27713

Telephone

+18887786481

Website

http://www.generalbiosystems.com/

Alerts

Be the first to know and let us send you an email when General Biosystems, Inc posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to General Biosystems, Inc:

General Biosystems, Inc